# Alzheon

> Alzheon, Inc. is a privately held clinical-stage biopharmaceutical company founded in 2013 and headquartered in Framingham, Massachusetts, developing oral small-molecule therapeutics and diagnostics for Alzheimer's disease and other neurodegenerative disorders. Its lead candidate, valiltramiprosate (ALZ-801), is a valine-conjugated prodrug of tramiprosate that blocks formation of neurotoxic soluble beta-amyloid oligomers; it holds FDA Fast Track designation and completed the pivotal APOLLOE4 Phase 3 trial in APOE4/4 homozygotes with early Alzheimer's disease.

Generated by API Evangelist on 2026-07-31. Alzheon does not publish an llms.txt of its own
(https://alzheon.com/llms.txt returns 404); this file was generated from the company's public
site and the artifacts in this repository.

## API posture

Alzheon operates **no product or developer API**. There is no developer portal, no API
documentation, no SDKs, no API keys, no MCP server and no A2A agent card. The `api.`,
`developer.`, `docs.`, `status.` and `trust.` subdomains do not resolve. No `/.well-known/`
document is served.

The one machine-readable contract the company serves is the standard **WordPress REST API**
on its corporate site, readable anonymously at `https://alzheon.com/wp-json`. It makes press
releases, science and pipeline pages, and the media library queryable without a key. Treat it
as an incidental content surface, not a supported product.

## APIs

- [Alzheon Content API (WordPress REST)](https://alzheon.com/wp-json): Read-only, anonymous access to 224 press releases and news items, 25 site pages, 624 media items, taxonomies, cross-content search and oEmbed. Write and administrative routes return 401.

## Specs

- [OpenAPI 3.1 — Alzheon Content API](openapi/alzheon-content-openapi.yml): Derived by API Evangelist from the provider's live route index; 24 verified anonymous read operations.
- [OpenAPI Overlay](overlays/alzheon-content-overlay.yaml): API Evangelist enhancements over the derived spec.

## Artifacts

- [Authentication profile](authentication/alzheon-authentication.yml): anonymous read; WordPress application passwords (HTTP Basic) for writes.
- [API conventions](conventions/alzheon-conventions.yml): pagination, ordering, filtering, caching, CORS, error envelope.
- [Error catalog](errors/alzheon-problem-types.yml): the WordPress REST error envelope (not RFC 9457).
- [Data model](data-model/alzheon-data-model.yml): posts, pages, media, taxonomies and their relationships.
- [Lifecycle](lifecycle/alzheon-lifecycle.yml): versioning, deprecation and status posture.
- [Conformance](conformance/alzheon-conformance.yml): which cross-cutting standards this surface does and does not meet.
- [Well-known index](well-known/alzheon-well-known.yml): every discovery path probed, with status.
- [Domain security](security/alzheon-domain-security.yml): TLS, HSTS, DNSSEC, CAA, SPF, DMARC probe results.
- [Agent skills](skills/_index.yml): packaged operating instructions grounded in real operationIds.

## Company

- [Alzheon](https://alzheon.com/): Corporate site.
- [About Alzheon](https://alzheon.com/people/about-us/): Company overview.
- [Pipeline](https://alzheon.com/science/pipeline/): Development programs.
- [Mechanism of action](https://alzheon.com/science/mechanism-of-action/): How valiltramiprosate works.
- [Publications](https://alzheon.com/science/publications/): Peer-reviewed publications.
- [Press releases](https://alzheon.com/media/press-releases/): Company announcements.
- [In the news](https://alzheon.com/media/in-the-news/): Third-party coverage.
- [Expanded access policy](https://alzheon.com/patients/expanded-access-policy/): Policy for patients.
- [Careers](https://alzheon.com/careers/): Open roles.
- [Contact](https://alzheon.com/contact/): Contact form.
- [Privacy policy](https://alzheon.com/privacy-policy/): Privacy policy. No public terms of use is published.
- [RSS feed](https://alzheon.com/feed/): Press releases and news, RSS 2.0.
- [LinkedIn](https://www.linkedin.com/company/alzheon)
- [X](https://x.com/Alzheon)

## Clinical trials

Registered on ClinicalTrials.gov, sponsored by Alzheon:

- [NCT04770220](https://clinicaltrials.gov/study/NCT04770220): APOLLOE4 — efficacy and safety of ALZ-801 in APOE4/4 early AD subjects (completed).
- [NCT06304883](https://clinicaltrials.gov/study/NCT06304883): Long-term extension of the Phase 3 study (terminated).
- [NCT04693520](https://clinicaltrials.gov/study/NCT04693520): Biomarker effects of ALZ-801 in APOE4 carriers with early Alzheimer's disease (completed).
- [NCT04157712](https://clinicaltrials.gov/study/NCT04157712): Multiple ascending dose study of ALZ-801 (completed).
- [NCT04585347](https://clinicaltrials.gov/study/NCT04585347): Single dose study of ALZ-801 prototype tablets (completed).

## Notes for agents

- No authentication is required for any operation in the OpenAPI. Do not attempt to obtain an API key — none is issued.
- Respect `robots.txt`: the site sets `Crawl-delay: 10`. Rate-limit accordingly.
- Responses carry `Cache-Control: max-age=600`; cache for at least ten minutes.
- Collection responses expose `X-WP-Total`, `X-WP-TotalPages` and RFC 8288 `Link` headers via CORS.
- Content is medical and regulatory in nature. ALZ-801/valiltramiprosate is an **investigational** agent that is not approved for marketing. Do not present pipeline or trial content as approved medical advice.